Day One Biopharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 155
- Market Cap
- $1.3B
- Website
- http://www.dayonebio.com
- Introduction
Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Day One Biopharmaceuticals, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT06752681
- Locations
- 🇺🇸
Site: 001-060, Indianapolis, Indiana, United States
🇺🇸Site: 001-059, Grand Rapids, Michigan, United States
🇺🇸Site: 001-057, San Antonio, Texas, United States
Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
- Conditions
- Low-grade Glioma
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Day One Biopharmaceuticals, Inc.
- Registration Number
- NCT05760586
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
- Conditions
- Low-grade GliomaPediatric Low-grade GliomaRapidly Accelerated Fibrosarcoma (RAF) Altered Glioma
- Interventions
- Drug: Chemotherapeutic Agent
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Day One Biopharmaceuticals, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05566795
- Locations
- 🇺🇸
Children's of Alabama, Birmingham, Alabama, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors
- Conditions
- MelanomaSolid TumorCRAF Gene AmplificationSpitzoid MelanomaPilocytic AstrocytomaPilocytic Astrocytoma, AdultNon Small Cell Lung CancerNon-Small Cell AdenocarcinomaColorectal CancerPancreatic Acinar Carcinoma
- Interventions
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Day One Biopharmaceuticals, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT04985604
- Locations
- 🇺🇸
The Angeles Clinic, Los Angeles, California, United States
🇺🇸Hoag Health, Newport Beach, California, United States
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Day One Biopharmaceuticals, Inc.
- Target Recruit Count
- 141
- Registration Number
- NCT04775485
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital, San Francisco, California, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Lurie Children's Hospital of Chicago, Chicago, Illinois, United States